Remove Antibody Remove Clinical Development Remove Drugs Remove Pharma Companies
article thumbnail

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

pharmaphorum

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98
article thumbnail

Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies

Delveinsight

The body produces antibodies to fight infections, but in the case of Autoimmune diseases, the antibodies start attacking the body’s cells, tissues, and organs. However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ambrx tries another IPO as it chases down HER2 rivals

pharmaphorum

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, its HER2-targeting antibody drug conjugate (ADC). ARX788 has fast-track status from the FDA for that indication.

article thumbnail

Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab

pharmaphorum

Genmab’s success has been founded on Darzalex (daratumumab), the blockbuster multiple myeloma drug that it developed in partnership with Johnson & Johnson’s Janssen unit. With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies.

article thumbnail

Biotech Outlook 2024: Enhanced Financing Environment and Strategic Adaptations Drive Industry Forward

XTalks

In the past two years, the industry has faced considerable challenges due to a constrained financing environment, forcing many emerging and early-stage biotech companies to restructure their operations, merge with other companies or narrow their research and development (R&D) efforts by shelving certain assets.

article thumbnail

CPV and AI: The Formula To Succeed In Biopharmaceutical Manufacturing

XTalks

Pharmaceutical development of novel drugs is a complex and tedious process. The information shared between different multidisciplinary teams is critical to reducing the cost and ultimately accelerating the path of bringing a drug to market.

article thumbnail

Are radiopharmaceuticals the next breakthrough in oncology?

pharmaphorum

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). The drug was added to Novartis’ portfolio through a $2.1 As with all developing treatment modalities, such issues are to be expected.